Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
Obesity · 2025
DOI: 10.1002/oby.70011 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2025. Written by Theresa Hunter Gibble and 5 co-authors. Institution: Eli Lilly and Company, Indianapolis, Indiana, USA. Major MEDLINE topics: Quality of Life, Obesity, Overweight, Anti-Obesity Agents. Cited 10 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Eli Lilly and Company.
Abstract (original language)
Objective
In SURMOUNT‐4, participants with obesity or overweight regained substantial weight after tirzepatide withdrawal, whereas continued treatment resulted in additional weight reduction. We evaluated the effect of continued tirzepatide treatment on health‐related quality of life (HRQoL) in SURMOUNT‐4.
Methods
Participants who achieved tirzepatide maximum tolerated dose (MTD; 10 or 15 mg; N = 670) during a 36‐week (W) lead‐in period were randomized (1:1) to continue receiving tirzepatide MTD or switch to placebo through W88. HRQoL was assessed using patient‐reported outcomes (PROs: SF‐36v2, IWQOL‐Lite‐CT, EQ‐5D‐5L). Post hoc analysis included changes in PROs by weight reduction categories and baseline Patient Global Impression of Status for physical activity response categories among tirzepatide‐treated participants and by weight regain categories in the placebo group.
Results
Tirzepatide treatment was associated with improved PROs from W0 to W36, and these improvements were maintained from W36 to W88 with continued tirzepatide treatment versus placebo. Tirzepatide‐treated participants with greater weight reduction and those with physical function limitations at baseline showed numerically greater improvements in PROs. Greater weight regain among participants who switched to placebo was associated with worsening of PROs.
Conclusions
In participants with overweight or obesity, continued tirzepatide treatment was associated with maintaining HRQoL improvement, while treatment withdrawal resulted in worsening of HRQoL. Trial Registration: ClinicalTrials.gov identifier NCT04660643.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.
ORCID profiles: Theresa Hunter Gibble, Harold Edward Bays
Funding
- Eli Lilly and Company
Cite
APA
Gibble, T. H., Cao, D., Murphy, M., Jouravskaya, I., Liao, B., & Bays, H. E. (2025). Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4. Obesity. https://doi.org/10.1002/oby.70011
Vancouver
Gibble TH, Cao D, Murphy M, Jouravskaya I, Liao B, Bays HE. Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4. Obesity. 2025. doi:10.1002/oby.70011
BibTeX
@article{Gibble2025,
author = {Gibble, Theresa Hunter and Cao, Dachuang and Murphy, Madhumita and Jouravskaya, Irina and Liao, Birong and Bays, Harold Edward},
title = {Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.70011}
}
EUVIMED